JP2023512701A5 - - Google Patents
Info
- Publication number
- JP2023512701A5 JP2023512701A5 JP2022547788A JP2022547788A JP2023512701A5 JP 2023512701 A5 JP2023512701 A5 JP 2023512701A5 JP 2022547788 A JP2022547788 A JP 2022547788A JP 2022547788 A JP2022547788 A JP 2022547788A JP 2023512701 A5 JP2023512701 A5 JP 2023512701A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- biomarker
- minutes
- sample
- nash
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025181395A JP2026021411A (ja) | 2020-02-10 | 2025-10-28 | 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972418P | 2020-02-10 | 2020-02-10 | |
| US62/972,418 | 2020-02-10 | ||
| PCT/US2021/017217 WO2021163034A1 (en) | 2020-02-10 | 2021-02-09 | Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025181395A Division JP2026021411A (ja) | 2020-02-10 | 2025-10-28 | 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512701A JP2023512701A (ja) | 2023-03-28 |
| JP2023512701A5 true JP2023512701A5 (https=) | 2024-01-30 |
| JP7766605B2 JP7766605B2 (ja) | 2025-11-10 |
Family
ID=74858782
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547788A Active JP7766605B2 (ja) | 2020-02-10 | 2021-02-09 | 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用 |
| JP2025181395A Pending JP2026021411A (ja) | 2020-02-10 | 2025-10-28 | 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025181395A Pending JP2026021411A (ja) | 2020-02-10 | 2025-10-28 | 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230071234A1 (https=) |
| EP (1) | EP4103948A1 (https=) |
| JP (2) | JP7766605B2 (https=) |
| KR (1) | KR20220140727A (https=) |
| CN (1) | CN115066616A (https=) |
| AU (1) | AU2021220787A1 (https=) |
| BR (1) | BR112022015303A2 (https=) |
| CA (2) | CA3300793A1 (https=) |
| IL (1) | IL295064A (https=) |
| MX (1) | MX2022009517A (https=) |
| PH (1) | PH12022552003A1 (https=) |
| WO (1) | WO2021163034A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023238881A1 (ja) * | 2022-06-07 | 2023-12-14 | 日東電工株式会社 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー |
| WO2025090996A1 (en) * | 2023-10-28 | 2025-05-01 | Novelna Inc. | Nafld detection proteins and methods of use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US7824871B2 (en) * | 2007-06-14 | 2010-11-02 | George Mason Intellectual Properties | Methods of diagnosing non-alcoholic steatohepatitis (NASH) |
| CN101802225B (zh) | 2007-07-17 | 2013-10-30 | 私募蛋白质体公司 | 检测样品的多元分析 |
| JP5781436B2 (ja) * | 2008-08-11 | 2015-09-24 | バンヤン・バイオマーカーズ・インコーポレーテッド | 神経学的状態のバイオマーカー検出方法およびアッセイ |
| SG186953A1 (en) | 2010-07-09 | 2013-02-28 | Somalogic Inc | Lung cancer biomarkers and uses thereof |
| CN103429753A (zh) | 2010-09-27 | 2013-12-04 | 私募蛋白质体公司 | 间皮瘤生物标记及其用途 |
| WO2014150198A2 (en) * | 2013-03-15 | 2014-09-25 | Somalogic, Inc. | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
| GB201320061D0 (en) * | 2013-11-13 | 2013-12-25 | Electrophoretics Ltd | Materials nad methods for diagnosis and prognosis of liver cancer |
| EP3110976B1 (en) * | 2014-02-27 | 2020-05-13 | Biogen MA Inc. | Method of assessing risk of pml |
| CA2978696A1 (en) * | 2015-02-03 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Novel methods for early identification of bone healing ability in injured patients |
| EP3303629A1 (en) * | 2015-06-05 | 2018-04-11 | Regulus Therapeutics Inc. | Non-alcoholic fatty liver disease biomarkers |
| KR20180029046A (ko) * | 2015-06-19 | 2018-03-19 | 세라 프로그노스틱스 인코포레이티드 | 조산 예측용 바이오마커 쌍 |
| CN107923918A (zh) * | 2015-09-09 | 2018-04-17 | 私募蛋白质体公司 | 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法 |
| US20210215711A1 (en) * | 2016-02-08 | 2021-07-15 | Somalogic, Inc. | Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof |
| US9725769B1 (en) * | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| CN111183360B (zh) * | 2017-07-19 | 2024-10-18 | 生物辐射欧洲有限公司 | 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合 |
-
2021
- 2021-02-09 KR KR1020227027222A patent/KR20220140727A/ko active Pending
- 2021-02-09 WO PCT/US2021/017217 patent/WO2021163034A1/en not_active Ceased
- 2021-02-09 EP EP21710121.1A patent/EP4103948A1/en active Pending
- 2021-02-09 MX MX2022009517A patent/MX2022009517A/es unknown
- 2021-02-09 PH PH1/2022/552003A patent/PH12022552003A1/en unknown
- 2021-02-09 BR BR112022015303A patent/BR112022015303A2/pt unknown
- 2021-02-09 IL IL295064A patent/IL295064A/en unknown
- 2021-02-09 US US17/796,748 patent/US20230071234A1/en active Pending
- 2021-02-09 CA CA3300793A patent/CA3300793A1/en active Pending
- 2021-02-09 CN CN202180012807.5A patent/CN115066616A/zh active Pending
- 2021-02-09 JP JP2022547788A patent/JP7766605B2/ja active Active
- 2021-02-09 AU AU2021220787A patent/AU2021220787A1/en active Pending
- 2021-02-09 CA CA3166923A patent/CA3166923A1/en active Pending
-
2025
- 2025-10-28 JP JP2025181395A patent/JP2026021411A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xanthakos et al. | AASLD Practice Statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children | |
| CN104769132B (zh) | 肝脏相关的炎性疾病的基因标记 | |
| JP7104689B2 (ja) | 有害事象を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ | |
| CN101175998A (zh) | 使用生化标志的肝脂肪变性诊断方法 | |
| JP2004507740A (ja) | 生化学マーカーを用いる繊維性疾患の診断方法 | |
| CN104160039B (zh) | 川崎病的生物标志物 | |
| Ali et al. | Varices in early histological stage primary biliary cirrhosis | |
| JP2019012077A (ja) | 炎症性肝疾患の診断のための方法および組成物 | |
| Kriss et al. | Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development | |
| Qi et al. | Candidate genes investigation for severe nonalcoholic fatty liver disease based on bioinformatics analysis | |
| CN113493829B (zh) | 生物标志物在肺动脉高压诊疗中的应用 | |
| JP2023512701A5 (https=) | ||
| Serling-Boyd et al. | Gastric antral vascular ectasia in systemic sclerosis: association with anti-RNA polymerase III and negative anti-nuclear antibodies | |
| Lantinga et al. | Spleen stiffness measurement across the spectrum of liver disease patients in real-world practice | |
| Akita et al. | Comprehensive proteomics profiling identifies circulating biomarkers to distinguish hypertrophic cardiomyopathy from other cardiomyopathies with left ventricular hypertrophy | |
| CN111647670A (zh) | 一种与肾病综合征相关的肠道菌属Faecalitalea及其应用 | |
| Reniers et al. | Does postoperative plasma IL-6 improve early prediction of infection after pulmonary cancer surgery? A two-centre prospective study | |
| CN107255711B (zh) | 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途 | |
| JP6876301B2 (ja) | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット | |
| Jamali | Non-alcoholic fatty liver disease: diagnosis and evaluation of disease severity | |
| US9506923B2 (en) | Method of diagnosing surgical site infections | |
| Tursi et al. | Accuracy of rapid fecal calprotectin test in monitoring inflammatory bowel diseases under treatment with TNFα antagonists | |
| Benbow et al. | Analysis of plasma tenascin-C in post-HCV cirrhosis: a prospective study | |
| US20200271666A1 (en) | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients | |
| EP3502691A1 (en) | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |